Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Eide, Christopher A., Zabriskie, Matthew S., Savage Stevens, Samantha L. · Cancer Cell · 2019